Ironwood Pharmaceuticals, Inc. - Class A (IRWD) — 分析摘要
Ironwood Pharmaceuticals, Inc. - Class A（IRWD）的市值为689.05百万美元，最近一年的营收同比增长了-15.7%。净利润率为8.1%。当前市盈率为5.3倍。
核心要点
- 营收同比变化-15.7%
- 净利润率8.1%
- 市盈率5.3倍
与PHARMACEUTICAL PREPARATIONS板块的其他公司相比，IRWD的营收增长为-15.7%，市盈率为5.3倍。
Ironwood Pharmaceuticals, Inc. - Class A (IRWD)
更新 — ET · 市场数据 POLYGON · 财务数据 SEC EDGAR
红旗与风险提示高风险信号
存在多项实质性红旗，在依赖任何估值输出前应先重点核查这些风险。
股东权益为负，可能意味着资产负债表承压。
营业利润率 (60.1%) 超过毛利率 (0.0%) — 请检查其他营业收入或数据分类问题
营业利润率为 60.1% — 异常高，通常仅见于垄断或IP密集型企业
Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.
行业
PHARMACEUTICAL PREPARATIONS
员工人数
100
总部
BOSTON, MA
Exchange
XNAS
基于 4 年财务数据的系统性竞争优势评估
此评估基于历史财务数据的量化分析，不构成投资建议。护城河评级可能随行业和竞争环境变化。
首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。
资本结构
现金流
免责声明：本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。